Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer
Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period. The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under the action of the enzyme, tamox...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-10-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/102 |
| _version_ | 1797696827843149824 |
|---|---|
| author | L. N. Lyubchenko M. G. Filippova T. A. Shendrikova L. G. Zhukova N. I. Mekhtieva O. V. Krokhina S. M. Portnoy |
| author_facet | L. N. Lyubchenko M. G. Filippova T. A. Shendrikova L. G. Zhukova N. I. Mekhtieva O. V. Krokhina S. M. Portnoy |
| author_sort | L. N. Lyubchenko |
| collection | DOAJ |
| description | Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period. The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under the action of the enzyme, tamoxifen passes into the metabolically active form, endoxyphene. Pharmacogenetic testing of the CYP2D6 gene in patients with hormone-positive breast cancer can help predict the effectiveness of therapy and assess the risk of side effects with the aim of improving long-term treatment outcomes. |
| first_indexed | 2024-03-12T03:31:45Z |
| format | Article |
| id | doaj.art-5df6a982317c425dbed172d493dee4f0 |
| institution | Directory Open Access Journal |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| last_indexed | 2024-03-12T03:31:45Z |
| publishDate | 2017-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj.art-5df6a982317c425dbed172d493dee4f02023-09-03T13:24:39ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872017-10-0143576610.17650/2313-805X-2017-4-3-57-6697Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancerL. N. Lyubchenko0M. G. Filippova1T. A. Shendrikova2L. G. Zhukova3N. I. Mekhtieva4O. V. Krokhina5S. M. Portnoy6ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period. The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under the action of the enzyme, tamoxifen passes into the metabolically active form, endoxyphene. Pharmacogenetic testing of the CYP2D6 gene in patients with hormone-positive breast cancer can help predict the effectiveness of therapy and assess the risk of side effects with the aim of improving long-term treatment outcomes.https://umo.abvpress.ru/jour/article/view/102тамоксифенфармакогенетичкское тестированиеген cyp2d6гормонотерапиярак молочной железы |
| spellingShingle | L. N. Lyubchenko M. G. Filippova T. A. Shendrikova L. G. Zhukova N. I. Mekhtieva O. V. Krokhina S. M. Portnoy Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer Успехи молекулярной онкологии тамоксифен фармакогенетичкское тестирование ген cyp2d6 гормонотерапия рак молочной железы |
| title | Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer |
| title_full | Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer |
| title_fullStr | Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer |
| title_full_unstemmed | Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer |
| title_short | Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer |
| title_sort | pharmacogenetic testing of allelic variants of the cyp2d6 gene in hormone positive breast cancer |
| topic | тамоксифен фармакогенетичкское тестирование ген cyp2d6 гормонотерапия рак молочной железы |
| url | https://umo.abvpress.ru/jour/article/view/102 |
| work_keys_str_mv | AT lnlyubchenko pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer AT mgfilippova pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer AT tashendrikova pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer AT lgzhukova pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer AT nimekhtieva pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer AT ovkrokhina pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer AT smportnoy pharmacogenetictestingofallelicvariantsofthecyp2d6geneinhormonepositivebreastcancer |